| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.6 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |